Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

pertuzumab

- PMLiVE

Buildings light up pink for breast cancer

Part of 'Wear it pink' day for  Breast Cancer Campaign

- PMLiVE

Novartis’ Lucentis wins fourth NICE recommendation

But eye drug only recommended after a price-cutting patient access scheme offered

- PMLiVE

Former Blair adviser to lead NHS England

Simon Stevens to succeed David Nicholson

- PMLiVE

Celgene’s Revlimid knocked-back by NICE

Final draft guidance from NICE does not recommend drug for rare bone marrow disorder

- PMLiVE

Roche signs biologics partnership with Samsung

Manufacturing deal follows investment in pharma firm's own capabilities

- PMLiVE

Amgen buys total filgrastim rights from Roche

Wrests control of white blood cell stimulator franchise

Novartis building

NICE backs Novartis/ ThromboGenics’ eye drug

Recommends Jetrea for NHS use in England and Wales to treat the rare disease vitreomacular traction

- PMLiVE

Walgreens: UK homecare sector could learn from the US

Pharmacy chain calls on UK to focus more on measuring the benefits of homecare

- PMLiVE

Pharmacy sales partners

How do you choose the right contract sales and marketing partner for your needs?

- PMLiVE

Homecare must be part of UK health debate, says NCHA

New CEO promises “greater leadership and clearer advocacy”

- PMLiVE

Astellas wins NICE backing for Xtandi in prostate cancer

England’s health guidance body says drug can be used in advanced cases of the disease

- PMLiVE

NICE unmoved by Pixuvri access scheme

England’s HTA body once again denies Cell Therapeutics' blood cancer treatment

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links